Poor interim results halt Lumenis' laser ablation trial
This article was originally published in Clinica
Executive Summary
Israeli firm Lumenis has elected to stop a trial of its laser ablation system for treating excessive menstrual bleeding, after interim results revealed insufficient efficacy to support a US FDA premarket approval application.